Conatus Pharmaceuticals Inc (CNAT) reported quarterly earnings results on Wednesday, Aug-3-2016. The company said it had a profit of $-0.30 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.08. Analysts had a consensus of $-0.38. During the same quarter in the previous year, the company posted $-0.31 EPS.
Many Wall Street Analysts have commented on Conatus Pharmaceuticals Inc. Conatus Pharmaceuticals Inc was Resumed by ROTH Capital to “Buy” on Jul 1, 2016.
Conatus Pharmaceuticals Inc opened for trading at $2.28 and hit $2.4 on the upside on Tusday, eventually ending the session at $2.33, with a gain of 1.75% or 0.04 points. The heightened volatility saw the trading volume jump to 1,44,428 shares. Company has a market cap of $50 M.
In a different news, on Apr 10, 2015, Daniel L Kisner (director) purchased 4,000 shares at $5.75 per share price.
Conatus Pharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of medicines to treat liver disease. The Company’s lead compound emricasan is an orally active pan-caspase protease inhibitor designed to reduce the activity of human caspases which are enzymes that mediate inflammation and apoptosis. It is conducting a clinical program to demonstrate the therapeutic benefit of emricasan in patients with chronic liver disease across the spectrum of liver disease including liver cirrhosis (LC); liver cirrhosis with portal hypertension (PH); post-orthotopic liver transplant (POLT) recipients with reestablished liver fibrosis post-transplant as a result of recurrent hepatitis C virus (HCV) infection who have achieved a sustained viral response (SVR) following HCV antiviral therapy (POLT-HCV-SVR) and non-alcoholic fatty liver disease (NAFLD) including patients with inflammatory and/or fibrotic non-alcoholic steatohepatitis (NASH).